SEATTLE, Aug. 7, 2012 (GLOBE NEWSWIRE) -- Plandai Biotechnology, Inc. (OTCBB:PLPL), a producer of highly Bioavailable plant extracts, is a recommended "BUY" in the recent KonLin Letter, Konrad Kuhn anticipates Plandai's income for 2012-2013 is projected to reach $27 million, accelerating within 5-yrs. to $90 million.
The KonLin letter states, "The fact that the U.S. nutritional supplements industry alone is over $29 billion annually and growing at 5.4% per year while the market for green tea is also in a high growth stage, with increasing annual volume growth rates between 13-14%." With this industry growth, Plandai is singled out as being ideally positioned with its exclusive CRS hydrodynamic processing and extraction system and vertical control of all aspects of supply from farming through distribution.
The KonLin Letter continues, "Plandai controls every aspect of the process, from growing the raw materials on its farms in South Africa to producing the extracts in-house. Thus Plandai is able to guarantee continuity of supply as well as quality throughout the whole process. In fact, Plandai recently announced the closing of a $13 mil. loan from the Land Bank of South Africa, which provides them with the capital necessary to move immediately into production of its highly Bioavailable green tea extract without causing any dilution to shareholders."
Unique to Plandai, the CRS processing and extraction system converts botanical matter from its natural state, which is difficult for the human body to absorb, into a highly bioavailable, or absorbable form. Medical research has demonstrated the benefits of many plant extracts, including green tea and tomatoes, in treating a host of illnesses including diabetes, malaria, obesity, high blood pressure and high cholesterol; however, the low bioavailability of these extracts makes them unsuitable for most applications. Plandai's Phytofare™ product line promises to be the first highly Bioavailable botanical extracts that can be used as an affordable additive to a variety of beverages, supplements and nutriceuticals.
About Plandai Biotechnology, Inc.
Plandai Biotechnology, Inc. focuses on the farming of whole fruits, vegetables and live plant material and the production of proprietary functional foods and botanical extracts for the health and wellness industry. Its principle holdings consist of land, farms and infrastructure in South Africa. Web site: http://www.plandaibiotech.com/
Safe Harbor Statement
The information provided may contain forward-looking statements and involve risks and uncertainties. Results, events and performances could vary from those contemplated. These statements involve risks and uncertainties which may cause actual results, expressed or implied, to differ from predicted outcomes. Risks and uncertainties include product demand, market competition, and Plandai's ability to meet current or future plans. Investors should study and understand all risks before making an investment decision. Readers are recommended not to place undue reliance on forward-looking statements or information. Plandaí is not obliged to publicly release revisions to any forward-looking statement, to reflect events or circumstances afterward, or to disclose unanticipated occurrences, except as required under applicable laws.